Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Hims & Hers CEO Andrew Dudum said in statement posted on X that the company will continue to offer access to personalized treatments "as allowed by law to meet patient needs." "Were also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications,'" Dudum said
Retatrutide should not be treated as an approved weight loss drug or obesity treatment unless an appropriate authority has approved that exact product for that use
Rather than guessing or overdoing it, patients should follow the plan recommended by their medical provider
YuhELJain PalrechaSLagemannGMKliotMWeinsteinPRBarbaroNMet al
US$ 20.76
US$ 29.39
US$ 29.73
US$ 23.29
